(PharmaNewsWire.Com, June 18, 2018 ) This report studies the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market status and forecast, categorizes the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
A biomarker is, according to the US National Institutes of Health, "a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention." Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images. Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins. We can discriminate four main types of molecular biomarkers: - Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA. - Transcriptomic biomarkers: Base on the analysis of RNA expression profiles. - Proteomic biomarkers: Base on the analysis of the protein profiles. - Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market. In the last several years, global market of Commercializing Biomarkers in Therapeutic and Diagnostic Applications developed rapidly, with an average growth rate of 8.49%. In 2015, the consumables revenue growth rate was about 8.5%, the services revenue growth rate was nearly 8.6%, and the consumables revenue growth rate was the highest among the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry. North America is the largest consumer of Commercializing Biomarkers, with the sales market share nearly 42%. The second place is Europe, following North America with the sales market share of 31%. Japan and China is also the important market, with the total sales marker share of 18.6%. The global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market is valued at 17200 million US$ in 2017 and will reach 24900 million US$ by the end of 2025, growing at a CAGR of 4.8% during 2018-2025. The major manufacturers covered in this report Roche Dako (Agilent Technologies) Merck BD Abbott Genesys Biolabs (20/20GeneSystems) Affymetrix Agendia ALMAC Arrayit Biocartic BG Medicine KEGG EXPRESSION Database Thermo Fisher BGI
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Consumables Services Software On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Oncology Cardiology Neurology Other
The study objectives of this report are: To analyze and study the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications sales, value, status (2013-2017) and forecast (2018-2025). Focuses on the key Commercializing Biomarkers in Therapeutic and Diagnostic Applications manufacturers, to study the sales, value, market share and development plans in future. Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis. To define, describe and forecast the market by type, application and region. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. To identify significant trends and factors driving or inhibiting the market growth. To analyze the opportunities in the market for stakeholders by identifying the high growth segments. To strategically analyze each submarket with respect to individual growth trend and their contribution to the market To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market To strategically profile the key players and comprehensively analyze their growth strategies.
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Research Report 2018 1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Overview
2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Competition by Manufacturers
3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Capacity, Production, Revenue (Value) by Region (2013-2018) 4 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Supply (Production), Consumption, Export, Import by Region (2013-2018)
5 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Production, Revenue (Value), Price Trend by Type
6 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Analysis by Application
7 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Manufacturers Profiles/Analysis 7.1 Roche 7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.1.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Category, Application and Specification 7.1.2.1 Product A 7.1.2.2 Product B 7.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 7.1.4 Main Business/Business Overview 7.2 Dako (Agilent Technologies) 7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Category, Application and Specification 7.2.2.1 Product A 7.2.2.2 Product B 7.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 7.2.4 Main Business/Business Overview 7.3 Merck 7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.3.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Category, Application and Specification 7.3.2.1 Product A 7.3.2.2 Product B 7.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 7.3.4 Main Business/Business Overview
8 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Manufacturing Cost Analysis 9 Industrial Chain, Sourcing Strategy and Downstream Buyers
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: